Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Terumo CV Group introduces new addition to CAPIOX Oxygenator portfolio

Terumo Cardiovascular Group introduces the newest addition to the CAPIOX Oxygenator portfolio – the CAPIOX FX Advance Oxygenator. The CAPIOX FX Advance replaces the current CAPIOX FX15 and FX25 line of oxygenators manufactured in Elkton, Maryland.

17 Feb 2016

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival.

16 Feb 2016

Nine researchers win EPSRC Healthcare Technologies Challenge Awards

Nine researchers, working on innovative projects that promise to improve healthcare diagnosis and treatment, across a wide spread of issues, were today announced as the first recipients of the Engineering and Physical Sciences Research Council's (EPSRC) Healthcare Technologies Challenge Awards.

15 Feb 2016

Pioneering technique shows promise for new medical diagnostics, targeted drug delivery

Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules--the enzymes.

12 Feb 2016

Implantable device could help deliver toxic cocktail of drugs directly to pancreatic tumors

A highly lethal cancer sometimes requires large doses of highly toxic drugs. However, a blitzkrieg approach can be unfeasible for some patients due to severe side effects. Now a powerhouse team of researchers at the University of North Carolina at Chapel Hill has revealed that an implantable device can deliver a particularly toxic cocktail of drugs directly to pancreatic tumors to stunt their growth or in some cases, shrink them - all while showing signs that the rest of the body would be spared toxic side effects.

9 Feb 2016

Asian manufacturers wear testing offered by Lucideon & Hong Kong standards and testing center collaboration

Lucideon, the international materials technology company, has announced that it has extended its collaboration agreement with the Hong Kong Standards and Testing Centre (STC) to include wear testing of orthopaedic hip and knee implants.

From Lucideon 3 Feb 2016

Halozyme closes $150 million royalty-backed debt transaction

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.

27 Jan 2016

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

Incidence of childhood myopia has more than doubled over last 50 years among American children

The largest study of childhood eye diseases ever undertaken in the U.S. confirms that the incidence of childhood myopia among American children has more than doubled over the last 50 years. The findings echo a troubling trend among adults and children in Asia, where 90 percent or more of the population have been diagnosed with myopia, up from 10 to 20 percent 60 years ago.

21 Jan 2016

Amorphous iron nanoparticles have potential to kill tumor cells

Amorphous iron nanoparticles have a specific toxicity in tumor cells. In the journal Angewandte Chemie, Chinese scientists describe their design and synthesis of a special amorphous state of nanoparticulate iron, which can locally release reactive iron species in the acidic and hydrogen peroxide rich environment of cancer cells, providing new possibilities for theranostics and chemodynamic therapies.

20 Jan 2016

Artificial pancreas moves closer to becoming a reality

As the accuracy, reliability, adoption, and successful use of Continuous Glucose Monitoring (CGM) continue to increase, the ultimate goal of combining CGM with an insulin pump and sophisticated algorithms for automating the control and suspension of insulin infusion--known as the "artificial pancreas"--moves closer to becoming a reality.

20 Jan 2016

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity.

20 Jan 2016

GBI Research says COPD therapeutics pipeline lacks innovation

Analysis from business intelligence provider GBI Research - Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation - states that while currently-available drugs aim to manage the frequency and severity of symptoms associated with COPD, none have been shown to modify long-term disease progression.

19 Jan 2016

Needle-free administration of anesthetic in the mouth could save costs, improve patient compliance

If you're scared of the dentist's needles you're not alone - but new research means you might not have to put off that appointment again. A study published in Colloids and Surfaces B: Biointerfaces reveals how the dentist could give you anesthetic using a tiny electric current instead of a needle.

19 Jan 2016

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

The cancer drug paclitaxel just got more effective. For the first time, researchers from the University of North Carolina at Chapel Hill have packaged it in containers derived from a patient's own immune system, protecting the drug from being destroyed by the body's own defenses and bringing the entire payload to the tumor.

18 Jan 2016

University of Copenhagen researchers develop new cell line to investigate brain drugs

Researchers from the Department of Pharmacy at the University of Copenhagen have developed a cell line, which may be used to investigate new drugs and help predict whether they are able to enter the brain.

18 Jan 2016

Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

Malaysian scientists are joining forces with Harvard University experts to help revolutionize the treatment of lung diseases -- the delivery of nanomedicine deep into places otherwise impossible to reach.

12 Jan 2016

New approach to package dual or more mixtures into a single capsule may boost drug efficiency

Researchers have developed a speedy, controllable way to get two or more ingredients into the same tiny capsule and only have them mix when triggered by a signal like vibrations or heat.

12 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

Drug Delivery News and Research

Further Reading

Terumo CV Group introduces new addition to CAPIOX Oxygenator portfolio

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Nine researchers win EPSRC Healthcare Technologies Challenge Awards

Pioneering technique shows promise for new medical diagnostics, targeted drug delivery

Implantable device could help deliver toxic cocktail of drugs directly to pancreatic tumors

Asian manufacturers wear testing offered by Lucideon & Hong Kong standards and testing center collaboration

Halozyme closes $150 million royalty-backed debt transaction

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Incidence of childhood myopia has more than doubled over last 50 years among American children

Amorphous iron nanoparticles have potential to kill tumor cells

Artificial pancreas moves closer to becoming a reality

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

GBI Research says COPD therapeutics pipeline lacks innovation

Needle-free administration of anesthetic in the mouth could save costs, improve patient compliance

Anti-cancer drug uses 50 times less chemo to effectively destroy drug-resistant lung cancer

University of Copenhagen researchers develop new cell line to investigate brain drugs

Malaysian scientists join forces with Harvard experts to help revolutionize lung disease treatment

New approach to package dual or more mixtures into a single capsule may boost drug efficiency

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

Event guide: World ADC San Diego eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo